akram-shehzad-23693-web

Shehzad Akram

Associate
Full contact info

Experience

UiPath Acquires Peak

March 12, 2025

Cooley advised UiPath (NYSE: PATH), a leading enterprise automation and artificial intelligence (AI) software company, on its acquisition of Peak, an AI-native company based in Manchester, United Kingdom.

Read more

Related contacts

Russell Anderson
Partner, London
Kevin Cooper
Partner, New York
Caroline Hobson
Partner, London
Aaron Pomeroy
Partner, Colorado
Leo Spicer-Phelps
Partner, London
Nicola Squire
Partner, London
Chris Stack
Partner, London
David Wilson
Partner, London
Christine Graham
Special Counsel, London
Rebecca Ross
Special Counsel, Washington, DC
Shehzad Akram
Associate, London
Olivia Anderson
Associate, London
Neelam Atwal
Associate, London
Harry Calkin
Associate, London
Harry Calkin
Associate, London
Cristina DeBiase
Associate, Boston
Rick Jantz
Associate, Santa Monica
Chris Lynn
Associate, London
Daniel Millard
Associate, London
Juan Nascimbene
Associate, London
Mo Swart
Associate, London
Dominic Taylor
Associate, London

Related Practices & Industries

Snyk Acquires Enso Security

June 12, 2023

Cooley advised Snyk, a leader in developer security, on its acquisition of Enso Security, pioneers of the industry’s first application security posture management (ASPM) solution.

Read more

Related contacts

Ben Shribman
Partner, London
Kerry Corrigan
Associate, London
Leo Spicer-Phelps
Partner, London
Juan Nascimbene
Associate, London
David Wilson
Partner, London
Nicola Squire
Partner, London
Shehzad Akram
Associate, London

Related Practices & Industries

Alvotech Agrees to Merge With SPAC Oaktree Acquisition Corp. II

December 9, 2021

Cooley advised Alvotech Holdings, a global biopharmaceutical company focused on the development and manufacturing of biosimilar medicines for patients worldwide, on its agreement to merge with special purpose acquisition company (SPAC) Oaktree Acquisition Corp. II. Lawyers Michal Berkner, Div Gupta, Nicolas Dumont and Jarrett Burks led the Cooley team advising Alvotech.

Read more

Related contacts

Div Gupta
Partner, New York
Wouter Deleersnyder
Associate, New York
Sonia Nath
Partner, Washington, DC
Phil Mitchell
Partner, New York
Aaron Pomeroy
Partner, Colorado
Barbara Mirza
Partner, Santa Monica
Stacey A. Bradford
Special Counsel, Washington, DC
Rick Jantz
Associate, Santa Monica
Stella Sarma
Partner, Brussels
Sharon Connaughton
Special Counsel, Washington, DC
Alexandria Ashour
Associate, San Diego
Chris Coulter
Partner, London
David Dalton
Associate, Santa Monica
Neelam Atwal
Associate, London
Chris Stack
Partner, London
Alan W. Tamarelli
Partner, New York
Karen Tsai
Special Counsel, Washington, DC
Wyatt Kernell
Associate, Colorado
Reid Hooper
Special Counsel, Washington, DC
Megan Browdie
Partner, Washington, DC
Sanya Sukduang
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
James Maton
Co-Partner in Charge – London, London
Shehzad Akram
Associate, London
Sarah Oliai
Associate, Washington, DC
Barbara Borden
Senior Counsel, San Diego
Nicola Squire
Partner, London
Peter Byrne
Partner, New York
Claire Keast-Butler
Co-Partner in Charge – London, London
Jill Simon
Senior Paralegal, New York
Xander Lee
Partner, Santa Monica
Calvin Lee
Associate, New York

Related Practices & Industries

Decibel on its $160 Million Agreement to Sell to Medallia Inc.

April 7, 2021

Advising Decibel, a leader in digital analytics, on its $160 million agreement to sell to Medallia Inc., the global leader in customer and employee experience and engagement.

Related contacts

Ben Shribman
Partner, London
Aaron Archer
Partner, London
Nicola Squire
Partner, London
Leo Spicer-Phelps
Partner, London
David Wilson
Partner, London
Paula Holland
Partner, London
Chris Stack
Partner, London
Shehzad Akram
Associate, London

Related Practices & Industries

Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million

July 11, 2019

Jazz Pharmaceuticals in its acquisition of Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization. Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments and incremental tiered royalties in mid-single digit percentage, based on any future net sales.

Related contacts

Marya Postner
Partner, Palo Alto
Geoffrey Spolyar
Partner, Boston
John Clark
Partner, London
Barbara Borden
Senior Counsel, San Diego
Dr. Jon Cousin
Partner, Washington, DC
Shehzad Akram
Associate, London
Rachel Thorn
Of counsel, New York

Related Practices & Industries

Admissions and credentials

England and Wales